<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380250</url>
  </required_header>
  <id_info>
    <org_study_id>0211SIB-0431</org_study_id>
    <nct_id>NCT00380250</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation</brief_title>
  <official_title>Phase 3, 12-Week, Multicenter, Double-Blind, Randomized, Efficacy and Safety Study of Lubiprostone for the Treatment of Irritable Bowel Syndrome With Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sucampo Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sucampo Pharma Americas, LLC</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the efficacy and safety of administration of
      lubiprostone in patients with irritable bowel syndrome with constipation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Responder Rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase during the month; AND did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.
Overall responder: responder for at least 2/3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Month 1 Spontaneous Bowel Movement (SBM) Frequency Rates Change From Baseline</measure>
    <time_frame>Change from baseline for month 1</time_frame>
    <description>SBMs are any bowel movement not associated with rescue medication use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Stool Consistency Change From Baseline</measure>
    <time_frame>Change from baseline for month 1</time_frame>
    <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Bowel Straining Change From Baseline</measure>
    <time_frame>Change from baseline for month 1</time_frame>
    <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Constipation Severity Change From Baseline</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Symptom Relief</measure>
    <time_frame>Change from baseline for month 1</time_frame>
    <description>Significantly worse = -3; Moderately worse = -2; A little bit worse = -1; Unchanged = 0; A little bit relieved=1; Moderately relieved=2; Significantly relieved = 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Change From Baseline</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire included 34 questions with 5 possible responses yielding the following sub-categories: dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual, and relationship Results range from 34 (low) to 100 (high); meaningful clinical improvement=14 point increase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Responder Rate</measure>
    <time_frame>month 2 (28 days)</time_frame>
    <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase during the month; AND did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Responder Rate</measure>
    <time_frame>month 3 (28 days)</time_frame>
    <description>Symptoms &gt;= Moderately relieved for 4 weeks/month or Significantly relieved for &gt;=2 weeks/month AND:
Rescue medication use does not increase during the month as compared to baseline;
No discontinuation during the month due to lack of efficacy;AND
No ratings during the month of Moderately worse or Significantly worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Responder Rate</measure>
    <time_frame>month 1 (28 days)</time_frame>
    <description>Symptoms &gt;= Moderately relieved for 4 weeks/month or Significantly relieved for &gt;=2 weeks/month AND:
Rescue medication use does not increase during the month as compared to baseline;
No discontinuation during the month due to lack of efficacy;AND
No ratings during the month of Moderately worse or Significantly worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Abdominal Bloating Change From Baseline</measure>
    <time_frame>Change from baseline for month 2</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Abdominal Bloating Change From Baseline</measure>
    <time_frame>Change from baseline for month 3</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Spontaneous Bowel Movement Frequency Rates Change From Baseline</measure>
    <time_frame>Change from baseline for month 2</time_frame>
    <description>Any bowel movement not associated with rescue medication use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Spontaneous Bowel Movement Frequency Rates Change From Baseline</measure>
    <time_frame>Change from baseline for month 3</time_frame>
    <description>Any bowel movement not associated with rescue medication use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Stool Consistency Change From Baseline</measure>
    <time_frame>Change from baseline for month 2</time_frame>
    <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Stool Consistency Change From Baseline</measure>
    <time_frame>Change from baseline for month 3</time_frame>
    <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Bowel Straining Change From Baseline</measure>
    <time_frame>Change from baseline for month 2</time_frame>
    <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Bowel Straining Change From Baseline</measure>
    <time_frame>Change from baseline for month 3</time_frame>
    <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Constipation Severity Change From Baseline</measure>
    <time_frame>Change from baseline for month 2</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Constipation Severity Change From Baseline</measure>
    <time_frame>Change from baseline for month 3</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Symptom Relief</measure>
    <time_frame>Change from baseline for month 2</time_frame>
    <description>Significantly worse = -3; Moderately worse = -2; A little bit worse = -1; Unchanged = 0; A little bit relieved=1; Moderately relieved=2; Significantly relieved = 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Symptom Relief</measure>
    <time_frame>Change from baseline for month 3</time_frame>
    <description>Significantly worse = -3; Moderately worse = -2; A little bit worse = -1; Unchanged = 0; A little bit relieved=1; Moderately relieved=2; Significantly relieved = 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Abdominal Bloating Change From Baseline</measure>
    <time_frame>Change from baseline for month 1</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Bowel Movement Frequency Rates Change From Baseline</measure>
    <time_frame>Change from baseline for month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Bowel Movement Frequency Rates Change From Baseline</measure>
    <time_frame>Change from baseline for month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Bowel Movement Frequency Rates Change From Baseline</measure>
    <time_frame>Change from baseline for month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 1 Abdominal Pain Change From Baseline</measure>
    <time_frame>Change from baseline for month 1</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 2 Abdominal Pain Change From Baseline</measure>
    <time_frame>Change from baseline for month 2</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month 3 Abdominal Pain Change From Baseline</measure>
    <time_frame>Change from baseline for month 3</time_frame>
    <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">590</enrollment>
  <condition>Irritable Bowel Syndrome With Constipation</condition>
  <arm_group>
    <arm_group_label>Lubiprostone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mcg capsule twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsule twice daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone</intervention_name>
    <arm_group_label>Lubiprostone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older

          -  Stable fiber therapy

          -  Normal colonoscopy/sigmoidoscopy

          -  Able to refrain from use of medications known to treat or associated with constipation
             symptoms

          -  Experiences abdominal discomfort/pain associated with bowel movements

          -  Reports decreased bowel movement frequency and/or other symptoms associated with
             constipation

        Exclusion Criteria:

          -  Diarrhea-predominant or alternating (diarrhea and constipation cycling) irritable
             bowel syndrome (IBS), or constipation other than that associated with IBS

          -  Open gastrointestinal or abdominal surgery prior to IBS onset

          -  Organic bowel disorder, mechanical bowel obstruction, pseudo-obstruction, unexplained
             weight loss or rectal bleeding

          -  Uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric
             disorder, other systemic disease, or abnormal laboratory tests per investigator
             discretion

          -  If female, is currently pregnant or nursing, or plans to become pregnant or nurse
             during the clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sucampo Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009 Feb 1;29(3):329-41. doi: 10.1111/j.1365-2036.2008.03881.x. Epub 2008 Nov 4.</citation>
    <PMID>19006537</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2006</study_first_posted>
  <results_first_submitted>October 7, 2008</results_first_submitted>
  <results_first_submitted_qc>January 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2014</results_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject entered 5/12/05; Last subject observation 7/18/08; Multicenter study performed at 65 study sites/centers across the US</recruitment_details>
      <pre_assignment_details>Subjects were enrolled after an up to 4 week screening period to meet inclusion/exclusion criteria and randomized on Day 0</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lubiprostone Study Period I</title>
          <description>Subjects who received active drug</description>
        </group>
        <group group_id="P2">
          <title>Placebo Study Period I</title>
          <description>Subjects who received placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Baseline participants data is taken from the intent to treat(ITT) population Whereas the Participant flow data is for all randomized subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Lubiprostone Study Period I</title>
          <description>Subjects who received active drug</description>
        </group>
        <group group_id="B2">
          <title>Placebo Study Period I</title>
          <description>Subjects who received placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="390"/>
            <count group_id="B2" value="193"/>
            <count group_id="B3" value="583"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" lower_limit="19" upper_limit="83"/>
                    <measurement group_id="B2" value="48.1" lower_limit="20" upper_limit="85"/>
                    <measurement group_id="B3" value="47.2" lower_limit="19" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="355"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="2.9"/>
                    <measurement group_id="B2" value="64.8" spread="3.09"/>
                    <measurement group_id="B3" value="64.9" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Spontaneous Bowel Movement (SBM) Frequency Rates Change From Baseline</title>
        <description>SBMs are any bowel movement not associated with rescue medication use.</description>
        <time_frame>Change from baseline for month 1</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Spontaneous Bowel Movement (SBM) Frequency Rates Change From Baseline</title>
          <description>SBMs are any bowel movement not associated with rescue medication use.</description>
          <population>ITT with LOCF</population>
          <units>SBM/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="2.462"/>
                    <measurement group_id="O2" value="1.21" spread="2.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.117</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Stool Consistency Change From Baseline</title>
        <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
        <time_frame>Change from baseline for month 1</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Stool Consistency Change From Baseline</title>
          <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.690"/>
                    <measurement group_id="O2" value="-0.33" spread="0.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Bowel Straining Change From Baseline</title>
        <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline for month 1</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Bowel Straining Change From Baseline</title>
          <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.739"/>
                    <measurement group_id="O2" value="-0.36" spread="0.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Constipation Severity Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline at 28 days</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Constipation Severity Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.602"/>
                    <measurement group_id="O2" value="-0.29" spread="0.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.159</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Symptom Relief</title>
        <description>Significantly worse = -3; Moderately worse = -2; A little bit worse = -1; Unchanged = 0; A little bit relieved=1; Moderately relieved=2; Significantly relieved = 3</description>
        <time_frame>Change from baseline for month 1</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Symptom Relief</title>
          <description>Significantly worse = -3; Moderately worse = -2; A little bit worse = -1; Unchanged = 0; A little bit relieved=1; Moderately relieved=2; Significantly relieved = 3</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="1.212"/>
                    <measurement group_id="O2" value="0.57" spread="1.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.378</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by pooled center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Change From Baseline</title>
        <description>Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire included 34 questions with 5 possible responses yielding the following sub-categories: dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual, and relationship Results range from 34 (low) to 100 (high); meaningful clinical improvement=14 point increase</description>
        <time_frame>Change from baseline at 12 weeks</time_frame>
        <population>ITT without LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Change From Baseline</title>
          <description>Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire included 34 questions with 5 possible responses yielding the following sub-categories: dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual, and relationship Results range from 34 (low) to 100 (high); meaningful clinical improvement=14 point increase</description>
          <population>ITT without LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="17.36"/>
                    <measurement group_id="O2" value="16.8" spread="19.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.588</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for clinical site</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Responder Rate</title>
        <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase during the month; AND did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.
Overall responder: responder for at least 2/3 months</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent-to-treat (ITT) without Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Responder Rate</title>
          <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase during the month; AND did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.
Overall responder: responder for at least 2/3 months</description>
          <population>Intent-to-treat (ITT) without Last Observation Carried Forward (LOCF)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>90% statistical power to detect 70.6% improvement in response with lubiprostone</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>No adjustment</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by pooled center, used to test the null hypothesis of equal rates between the 2 groups vs. the alternate hypothesis of non-equality</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Responder Rate</title>
        <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase during the month; AND did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
        <time_frame>month 2 (28 days)</time_frame>
        <population>ITT without LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Responder Rate</title>
          <description>Monthly responder: &gt;=Moderately relieved symptoms 4 weeks/month or Significantly relieved &gt;= 2 weeks/month IF:
Rescue med use did not increase during the month; AND did not discontinue during the month for lack of efficacy; AND no Moderately worse or Significantly worse response in month.</description>
          <population>ITT without LOCF</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>Sequential closed testing procedures were employed</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by pooled center, used to test the null hypothesis of equal rates between the 2 groups vs. the alternate hypothesis of non-equality</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Responder Rate</title>
        <description>Symptoms &gt;= Moderately relieved for 4 weeks/month or Significantly relieved for &gt;=2 weeks/month AND:
Rescue medication use does not increase during the month as compared to baseline;
No discontinuation during the month due to lack of efficacy;AND
No ratings during the month of Moderately worse or Significantly worse.</description>
        <time_frame>month 3 (28 days)</time_frame>
        <population>ITT without LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Responder Rate</title>
          <description>Symptoms &gt;= Moderately relieved for 4 weeks/month or Significantly relieved for &gt;=2 weeks/month AND:
Rescue medication use does not increase during the month as compared to baseline;
No discontinuation during the month due to lack of efficacy;AND
No ratings during the month of Moderately worse or Significantly worse.</description>
          <population>ITT without LOCF</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <p_value_desc>Sequential closed testing procedures were employed</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by pooled center, used to test the null hypothesis of equal rates between the 2 groups vs. the alternate hypothesis of non-equality</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Responder Rate</title>
        <description>Symptoms &gt;= Moderately relieved for 4 weeks/month or Significantly relieved for &gt;=2 weeks/month AND:
Rescue medication use does not increase during the month as compared to baseline;
No discontinuation during the month due to lack of efficacy;AND
No ratings during the month of Moderately worse or Significantly worse.</description>
        <time_frame>month 1 (28 days)</time_frame>
        <population>ITT without LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Responder Rate</title>
          <description>Symptoms &gt;= Moderately relieved for 4 weeks/month or Significantly relieved for &gt;=2 weeks/month AND:
Rescue medication use does not increase during the month as compared to baseline;
No discontinuation during the month due to lack of efficacy;AND
No ratings during the month of Moderately worse or Significantly worse.</description>
          <population>ITT without LOCF</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.098</p_value>
            <p_value_desc>Sequential closed testing procedures were employed</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by pooled center, used to test the null hypothesis of equal rates between the 2 groups vs. the alternate hypothesis of non-equality</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Abdominal Bloating Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline for month 2</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Abdominal Bloating Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.693"/>
                    <measurement group_id="O2" value="-0.35" spread="0.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.286</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Abdominal Bloating Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline for month 3</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Abdominal Bloating Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.734"/>
                    <measurement group_id="O2" value="-0.37" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.337</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Spontaneous Bowel Movement Frequency Rates Change From Baseline</title>
        <description>Any bowel movement not associated with rescue medication use</description>
        <time_frame>Change from baseline for month 2</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Spontaneous Bowel Movement Frequency Rates Change From Baseline</title>
          <description>Any bowel movement not associated with rescue medication use</description>
          <population>ITT with LOCF</population>
          <units>SBM/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="2.795"/>
                    <measurement group_id="O2" value="1.41" spread="2.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.334</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Spontaneous Bowel Movement Frequency Rates Change From Baseline</title>
        <description>Any bowel movement not associated with rescue medication use</description>
        <time_frame>Change from baseline for month 3</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Spontaneous Bowel Movement Frequency Rates Change From Baseline</title>
          <description>Any bowel movement not associated with rescue medication use</description>
          <population>ITT with LOCF</population>
          <units>SBM/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="2.990"/>
                    <measurement group_id="O2" value="1.39" spread="2.851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.242</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Stool Consistency Change From Baseline</title>
        <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
        <time_frame>Change from baseline for month 2</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Stool Consistency Change From Baseline</title>
          <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.756"/>
                    <measurement group_id="O2" value="-0.38" spread="0.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Stool Consistency Change From Baseline</title>
        <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
        <time_frame>Change from baseline for month 3</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Stool Consistency Change From Baseline</title>
          <description>0 = Very loose (watery), 1 = Loose, 2 = Normal, 3 = Hard, 4 = Very hard (little balls)</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.725"/>
                    <measurement group_id="O2" value="-0.41" spread="0.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.130</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Bowel Straining Change From Baseline</title>
        <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline for month 2</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Bowel Straining Change From Baseline</title>
          <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.846"/>
                    <measurement group_id="O2" value="-0.43" spread="0.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Bowel Straining Change From Baseline</title>
        <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline for month 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Bowel Straining Change From Baseline</title>
          <description>0 = Absent,1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.847"/>
                    <measurement group_id="O2" value="-0.45" spread="0.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.348</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Constipation Severity Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline for month 2</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Constipation Severity Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.719"/>
                    <measurement group_id="O2" value="-0.40" spread="0.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Constipation Severity Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline for month 3</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Constipation Severity Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.755"/>
                    <measurement group_id="O2" value="-0.41" spread="0.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>van Elteren nonparametric test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Symptom Relief</title>
        <description>Significantly worse = -3; Moderately worse = -2; A little bit worse = -1; Unchanged = 0; A little bit relieved=1; Moderately relieved=2; Significantly relieved = 3</description>
        <time_frame>Change from baseline for month 2</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Symptom Relief</title>
          <description>Significantly worse = -3; Moderately worse = -2; A little bit worse = -1; Unchanged = 0; A little bit relieved=1; Moderately relieved=2; Significantly relieved = 3</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="1.278"/>
                    <measurement group_id="O2" value="0.59" spread="1.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.144</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by pooled center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Symptom Relief</title>
        <description>Significantly worse = -3; Moderately worse = -2; A little bit worse = -1; Unchanged = 0; A little bit relieved=1; Moderately relieved=2; Significantly relieved = 3</description>
        <time_frame>Change from baseline for month 3</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Symptom Relief</title>
          <description>Significantly worse = -3; Moderately worse = -2; A little bit worse = -1; Unchanged = 0; A little bit relieved=1; Moderately relieved=2; Significantly relieved = 3</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="1.259"/>
                    <measurement group_id="O2" value="0.57" spread="1.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted by pooled center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Abdominal Bloating Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline for month 1</time_frame>
        <population>ITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Abdominal Bloating Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <population>ITT with LOCF</population>
          <units>Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.585"/>
                    <measurement group_id="O2" value="-0.24" spread="0.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.615</p_value>
            <method>van Elteren nonparametic test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Bowel Movement Frequency Rates Change From Baseline</title>
        <time_frame>Change from baseline for month 1</time_frame>
        <population>ITT, with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Bowel Movement Frequency Rates Change From Baseline</title>
          <population>ITT, with LOCF</population>
          <units>BM/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="2.234"/>
                    <measurement group_id="O2" value="0.88" spread="2.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>van Elteren nonparametric test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Bowel Movement Frequency Rates Change From Baseline</title>
        <time_frame>Change from baseline for month 2</time_frame>
        <population>ITT, with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Bowel Movement Frequency Rates Change From Baseline</title>
          <population>ITT, with LOCF</population>
          <units>BM/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="2.440"/>
                    <measurement group_id="O2" value="1.10" spread="2.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.483</p_value>
            <method>van Elteren nonparametric test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Bowel Movement Frequency Rates Change From Baseline</title>
        <time_frame>Change from baseline for month 3</time_frame>
        <population>ITT, with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Bowel Movement Frequency Rates Change From Baseline</title>
          <population>ITT, with LOCF</population>
          <units>BM/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="2.744"/>
                    <measurement group_id="O2" value="1.04" spread="2.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.491</p_value>
            <method>van Elteren nonparametric test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 1 Abdominal Pain Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline for month 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 1 Abdominal Pain Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <units>Scale Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.588"/>
                    <measurement group_id="O2" value="-0.27" spread="0.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 2 Abdominal Pain Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline for month 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 2 Abdominal Pain Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <units>Scale Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.695"/>
                    <measurement group_id="O2" value="-0.37" spread="0.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Month 3 Abdominal Pain Change From Baseline</title>
        <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
        <time_frame>Change from baseline for month 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone Study Period I</title>
            <description>Subjects who received active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo Study Period I</title>
            <description>Subjects who received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Month 3 Abdominal Pain Change From Baseline</title>
          <description>0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Very Severe</description>
          <units>Scale Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.722"/>
                    <measurement group_id="O2" value="-0.36" spread="0.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren nonparametric test</method>
            <method_desc>Adjusted for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 weeks</time_frame>
      <desc>Any subject who took at least 1 dose of study medication made up the safety population. The N of this population is different from both the total subjects randomized and the ITT population</desc>
      <group_list>
        <group group_id="E1">
          <title>Lubiprostone Study Period I</title>
          <description>8 mcg capsules twice daily (BID)</description>
        </group>
        <group group_id="E2">
          <title>Placebo Study Period I</title>
          <description>Matching placebo capsules twice daily (BID)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid gland cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75"/>
                <counts group_id="E2" subjects_affected="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="396"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="396"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="396"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Taryn Joswick</name_or_title>
      <organization>Sucampo Pharmaceuticals, Inc.</organization>
      <phone>301-961-3400</phone>
      <email>info@sucampo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

